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Use of statins and the risk of 
dementia and mild cognitive 
impairment: A systematic review 
and meta-analysis
Che-Sheng Chu1,2, Ping-Tao Tseng  3,4, Brendon Stubbs5,6,7, Tien-Yu Chen8,9, Chia-Hung Tang10, 
Dian-Jeng Li  11,12, Wei-Cheng Yang13, Yen-Wen Chen14, Ching-Kuan Wu2, Nicola Veronese15, 
Andre F. Carvalho16,17, Brisa S. Fernandes18,19, Nathan Herrmann20 & Pao-Yen Lin21,22
We conducted a systematic review and meta-analysis to investigate whether the use of statins could be 
associated with the risk of all-caused dementia, Alzheimer’s disease (AD), vascular dementia (VaD), and 
mild cognitive impairment (MCI). Major electronic databases were searched until December 27th, 2017 
for studies investigating use of statins and incident cognitive decline in adults. Random-effects meta-
analyses calculating relative risks (RRs) were conducted to synthesize effect sizes of individual studies. 
Twenty-five studies met eligibility criteria. Use of statins was significantly associated with a reduced risk 
of all-caused dementia (k = 16 studies, adjusted RR (aRR) = 0.849, 95% CI = 0.787–0.916, p = 0.000), AD 
(k = 14, aRR = 0.719, 95% CI = 0.576–0.899, p = 0.004), and MCI (k = 6, aRR = 0.737, 95% CI = 0.556–
0.976, p = 0.033), but no meaningful effects on incident VaD (k = 3, aRR = 1.012, 95% CI = 0.620–1.652, 
p = 0.961). Subgroup analysis suggested that hydrophilic statins were associated with reduced risk of 
all-caused dementia (aRR = 0.877; CI = 0.818–0.940; p = 0.000) and possibly lower AD risk (aRR = 0.619; 
CI = 0.383–1.000; p = 0.050). Lipophilic statins were associated with reduced risk of AD (aRR = 0.639; 
CI = 0.449–0.908; p = 0.013) but not all-caused dementia (aRR = 0.738; CI = 0.475–1.146; p = 0.176). In 
conclusion, our meta-analysis suggests that the use of statins may reduce the risk of all-type dementia, 
AD, and MCI, but not of incident VaD.
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As the life expectancy is getting longer worldwide, the number of people affected by cognitive decline and demen-
tia is steadily increasing1. Dementia is an age-related neurodegenerative disease, characterized by a progressive 
decline in cognitive function often encompassing several domains (e.g. memory, attention, language, and prob-
lem solving)2. According to the World Health Organization (WHO) estimates, the number of individuals affected 
by dementia is expected to triple by 2050, with the rapid aging of populations globally [http://www.who.int/age-
ing/en/]. Meanwhile, the individual, societal and healthcare costs associated with dementia are steeply increased3. 
Unsurprisingly, the prevention of cognitive decline and dementia is a worldwide public health issue4.
Recently, interest has arisen in the potential for statins to delay cognitive decline in people with older age. 
Statins are drugs that inhibit 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase5. Statins not only 
lower serum cholesterol levels, but also inhibit pivotal enzymatic reactions (e.g. the isoprenylation of a subset 
of GTPases)6 that lead to amyloid deposition and plaque formation; both are considered cornerstone pathways 
underpinning the development of Alzheimer’s disease (AD)7. Epidemiological data have supported a possible 
association between the use of statins and the risk of dementia, but evidence appears controversial. Some obser-
vational studies have demonstrated that statins reduce the risk of dementia or incident AD8–17, whereas several 
others have failed to replicate those findings18–25. Several possible factors may contribute to discrepant findings 
across studies. First, statins might exhibit neuroprotective effects limited only to earliest stages of AD8,26. Some 
studies have shown that statins exert more robust protective effects upon cognition for subjects younger than 80 
at baseline13,14. Second, the degree of exposure (i.e. time and dose of statins use) could influence outcomes14,15. 
Third, clinicians might not be willing to prescribe statins for patients with pre-existing poor cognitive status 
due to concerns about possible treatment-related side effects, and lesser benefit because of expected diminished 
life expectancy27,28. Fourth, ApoE genotype might alter the association between use of statins and incidence of 
dementia. One recent study has shown that statins may be more beneficial in AD patients with homozygous 
ApoE4 genotypes29. Finally, the effects of confounders may limit inferences from observational studies30, and 
hence may vary depending on both the specific population being examined and potential confounding variables 
that are controlled for in multivariable analysis.
Several meta-analyses of observational studies have previously been conducted to examine the potential role 
of statins on incident mild cognitive impairment (MCI) or dementia, but have provided conflicting results thus 
far31–36. A meta-analysis including case-control and cohort studies demonstrated statins use did not confer a 
protective effect on the risk of dementia or AD35. However, another meta-analysis of 8 prospective cohort studies 
found that the use of statins was associated with a significantly reduced relative risks (RRs) of dementia by 39%32. 
In the most recent study published in 2013, Richardson et al. found a reduced RR for all-caused dementia, AD, 
or MCI based on observational studies, while 16 cohort studies were available when this previous meta-analysis 
was conducted37. The majority of these meta-analyses have focused solely on statins use and the risk of all-caused 
dementia and AD. Only one meta-analysis had examined a possible effect in reducing the incidence of MCI37 and 
to our knowledge, no previous meta-analyses has separately assessed the risk of vascular dementia (VaD). Several 
new reports (including new studies which included different (i.e. Asian) populations38,39 have been published in 
more recent years36,38–41. In addition, possibly due tolimited evidence no previous meta-analysis has explored 
potential sources of heterogeneity across studies.
Therefore, the current systematic review and meta-analysis aims to reappraise available evidence from pro-
spective studies, which investigated whether statins use could diminish incident all-caused dementia, AD, VaD, 
and MCI. In addition, due to the anticipated larger current evidence base, we aimed to explore potential sources 
of heterogeneity across studies.
Results
Studies Included in the Meta-analysis. Overall, 3,824 unique references were identified after database 
searching, while 27 were identified from other sources. Of those, 2402 were excluded after title/abstract screen-
ing because they are not related to this meta-analysis; the main target of current meta-analysis aimed to discuss 
the association between statins and dementia. Total 238 articles were scrutinized, and 213 were excluded with 
reasons (see Supplementary material Tables S1 and S2). Finally, 25 articles met inclusion criteria. The flow chart 
of the search strategy and results is depicted in Fig. 1. The mean total numbers of covariates adjusted were 7.40 
(Standard deviation [SD]: 3.38) and mean duration of follow-up periods were 6.95 (SD: 5.39) years.
In total, twenty-five articles met the inclusion criteria and were included in the current systematic review and 
meta-analysis (Table 1)8–10,13,16,18,19,21–23,25,36,38,40–51. Table 1 provides characteristics of included studies.
Among included studies, 16 studies investigated the association of statins use and incident all-caused demen-
tia (N = 2,745,149, mean age 59.3 years, male = 67.3%, incident cases = 35,688), 14 studies assessed the association 
of statins use and incident AD (N = 52,218, mean age 71.3 years, male = 45.3%, incident cases = 3120), 3 studies 
investigated VaD (N = 5,987, mean age 77.2 years, male = 42.5%, incident cases = 422), and 6 studies investigated 
MCI (N = 6,808, mean age 68.4 years, male = 33.2%, incident cases of four studies9,36,42,48 = 359), respectively. 
Across those 25 studies, Supplementary material Table S3 provides a list of potential confounders considered in 
the multivariable models in each study, and the total number of covariates considered in the most fully adjusted 
risk estimate (e.g. aRRs) in each included study.
Methodological Quality Assessment. The average NOS were 7.72 with interquartile range (IQR) (7.00–
8.00). The score in each domain of the NOS is provided in Supplementary material Table S4.
Statins and Incident All-caused Dementia. Across 16 studies8,9,18,21,22,25,38,40–44,46,47,49,50, participants 
who received statins were significantly less likely to develop all-caused dementia compared to those who were 
not treated with statins (aRR from 16 studies = 0.849, 95% CI = 0.787–0.916, p < 0.001) (Fig. 2). There was no 
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evidence of publication bias according to Egger’s test (t value = 1.816, df = 14, p = 0.091). However, heterogeneity 
was verified (Q value = 29.778, df = 15, I2 = 49.627, p = 0.013).
Sources of Heterogeneity. Subgroup analysis showed the use of hydrophilic statins were associated 
reduced risk of all-caused dementia (aRRs = 0.877; CI = 0.818–0.940; p < 0.001), whereas the use of lipophilic 
statins were not associated with this outcome (aRR = 0.738; CI = 0.475–1.146; p = 0.176) (Fig. 3A). Regarding 
status of statins use (current and former users), lower risk of all-caused dementia was found among current users 
(aRR = 0.828; CI = 0.692–0.990; p = 0.039) but not in former users (aRR = 1.125, CI = 0.818–1.547, p = 0.470) 
(Fig. 3B). In the meta-regression analyses, mean age, percentage of male, education in years, study duration, 
percentage of cardiovascular, cerebrovascular disease, DM, HTN, smoking, ApoE4 status, BMI > 25, choles-
terol > 200 mg/dl, total Newcastle scores, and total number of covariates used in the multivariate analyses did 
not seem to contribute to heterogeneity. The percentage of white population (slope = 0.005; p = 0.006) and most 
notably the percentage of cholesterol > 200 mg/dl (slope = 0.018; p = 0.009) emerged as significant moderators of 
this outcome (Supplementary material Table S5).
Statins and Incident Alzheimer’s Disease. Across 14 studies8,10,13,16,18,19,21–23,25,38,41,42,51, participants who 
were treated with statins were significantly less likely to develop AD compared to those who were not treated with 
Figure 1. PRISMA flowchart of study selection for the current systematic review and meta-analysis.
Figure 2. Forest plot of random-effects meta-analyses of the use of statins and incidence of all-caused 
dementia.
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Author (year) Criteria Study design
Mean age (SD)
Male (%)
Subjects
(case by statins use 
or total)*
Follow up
(years) Outcome*
Definition of statins
use
Confirm
statins use
Dropouts
(%)
Harding 
(2017)35 MCI
a Prospective 
cohort
69.7
0 175(SU/NSU: 3/14) 8.4 MCI Any use Self-reported n/a
Chitnis (2015)39 ICD-9 Retrospective cohort
74.4 (9.2)
47
8062 (SU/NSU: 
512/623) 3 Dementia
Current use >15
days during month EMR
e n/a
Hendrie 
(2015)40
DSM-IV
ICD-10
Prospective 
cohort
76.6 (4.9)
30.3
974 (Dementia, SU/
NSU: 9/56);
965 (AD, SU/NSU: 
7/49)
8 Dementia;AD Any use
Medication 
inspection n/a
Chen (2014)37 DSM-IV Retrospective cohort
66.8 (8.6)
52.3
18170 (Dementia, 
SU/NSU:
53/824); 18013 (AD, 
SU/NSU: 41/679)
8 Dementia;AD
Regular use (more than 
one year) EMR
f n/a
Ancelin 
(2012)18
DSM-IV
NINCDS-ADRDA
Prospective 
cohort
74
40
6830 (Dementia, 
483; AD, 332) 7
Dementia;
AD Use at baseline
Medication 
inspection n/a
Bettermann 
(2012)8 n/a
Prospective 
cohort
78.6 (3.3)
54
2587 (Dementia, 
324; AD, 212; VaD, 
148)
6 Dementia;AD; VaD Any use
Medication 
inspection n/a
Beydoun 
(2011)41
DSM-III-R
NINCDS-ADRDA
Petersen criteria
Prospective 
cohort
58.0 (18)
62
1604 (Dementia, 
259); 1308
(MCI, 133)
25 Dementia;AD; MCI Ever use
Medication 
inspection n/a
Parikh (2011)43 n/a Retrospectivecohort
75.5 (6.1)
98
377838 (SU/NSU: 
5316/9246) 2 Dementia Any use (through study)
Pharmacy 
records n/a
Hippisley-Cox 
(2010)42 n/a
Prospective 
cohort
45.8 (14.1)
45 2004692 (8784) Up to 6 Dementia New users EMR
g n/a
Li (2010)13 DSM-IVNINCDS-ADRDA
Prospective 
cohort
75.4 (6.2)
40.7 3099 (263) 6.1 AD Any use (3 consecutive)
Pharmacy 
records 8%
Haag (2009)10 DSM-III-RNINCDS-ADRDA
Prospective 
cohort
69.4 (9.1)
40 6992 (466) 9 AD Any use
Pharmacy 
records n/a
Solomon 
(2009)45 n/a
Prospective
cohort
71.8 (4.9)
46.3 14294 (1301) 20 Dementia n/a EMR
h n/a
Schneider 
(2009)44 MCI
b Prospective 
cohort
70 to 80
0 293 (n/a) 3 MCI
Continuous use (2 
consecutive) n/a n/a
Arvanitakis 
(2008)19 n/a
Prospective 
cohort
74.9 (7.0)
31.3
929 (SU/NSU:: 
16/175) Up to 12 AD Any use
Medication 
inspection 8%
Cramer (2008)9
DSM-IV
NINCDS-ADRDA
MCIc
Prospective 
cohort
70.4 (6.0)
42
1674 (Dementia, 
SU/NSU:
28/102; MCI, 130)
5 Dementia;MCI Any use
Medication 
inspection 31%
Sparks (2008)16 ICD-9NINCDS-ADRDA
Clinical trial 
cohort
74.8 (3.8)
46
2068 (SU/NSU: 
4/20; MCI, n/a) 4 AD; MCI
Continuous use at all 
visits Self-reported 12%
Li (2007)50 DSM-IVNINCDS-ADRDA
Prospective 
cohort
74.1 (3.8)
67.2 110 (12) n/a AD Any use (3 consecutive)
Pharmacy 
records n/a
Szwast (2007)49 DSM-III-RICD-10
Prospective 
cohort
77.3 (5.3)
38.1
1141 (SU/NSU: 
3/29) 3 Dementia Use at baseline
Medication 
inspection 28%
Wolozin 
(2007)48 ICD-9
Prospective 
cohort
75
94
1290071 (SU/NSU: 
3361/3359) 3 Dementia
Continuous use in first 
7 months EMR
i n/a
Zigman 
(2007)46 n/a
Prospective 
cohort
41 to 78
22.8 123 (SU/NSU: 8/30) 5.5 Dementia Any use
Medication 
inspection n/a
Rea (2005)22 NINCDS-ADRDA Prospective cohort
75
40
2798 (Dementia, 
SU/NSU:
38/438; AD, SU/
NSU: 21/216;
VaD, SU/NSU: 7/55)
5 Dementia;AD; VaD Any use
Medication 
inspection n/a
Zandi (2005)25 DSM-III-RNINCDS-ADRDA
Cross-sectional 
and prospective 
cohort
75.5 (7.1)
42.8
3308 (Dementia, 
SU/NSU:
8/174; AD, SU/NSU: 
4/98)
3 Dementia; AD Any use Medication inspection 27%
Li (2004)21 DSM-IVNINCDS-ADRDA
Prospective 
cohort
75.1 (6.1)
40.2
2356 (Dementia, 
SU/NSU: 41/271; 
AD, 168)
6 Dementia; AD Any use (2 consecutive within 6 months)
Pharmacy 
records 9%
Reitz (2004)23 NINCDS-ADRDA
Cross-sectional 
and prospective 
cohort
78.4 (6.2)
31.7
2126 (AD, 119; 
VaD, 54) 4.8 ± 2.9 AD; VaD Any use
Medication 
inspection 45.1%
Yaffe (2002)47 MCId Clinical trial cohort
<80
0
2126 (SU/NSU: 
37/42) 4 MCI Current use
Medication 
inspection n/a
Table 1. Characteristics of included studies. aDefined as decline in Consortium to Establish a Registry for 
Alzheimer’s Disease (CERAD) word list. bDefined by Trails-A and B, HVLT-immediate and delayed recall. 
cDefined as decline in 3MS, SEVLT. dDefined by level of 3 MS examination. Note: the datasets included in 
this meta-analysis were extracted from the peer-reviewed articles which are not available from open access 
sources. Name of the EMR of each study: eMedicare Advantage Prescription Drug plan [MAPD] in Texas; 
fNational Health Insurance Research Database in Taiwan; gEgton Medical Information System [EMIS] 
in England and Wales; hHospital Discharge Registry and Drug Reimbursement Registry in Finland; iUS 
Veterans Affairs database. Abbreviation: Abbreviations: 3MS: Modified mini-mental state examination; 
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statins (aRR from 14 studies = 0.719, 95% CI = 0.576–0.899, p = 0.004). There was evidence of publication bias 
through Egger’s test was observed (t value = 2.307, df = 12, p = 0.039) (Fig. 4A). We used Duval and Tweedie’s 
trim and fill procedure toward the right to adjust effect size estimates to publication bias and the results remained 
significant (aRR = 0.814, 95% CI = 0.713–0.930). In addition, heterogeneity was large (Q value = 28.779, df = 13, 
I2 = 54.828, p = 0.007). Therefore, potential sources of heterogeneity were explored.
Sources of Heterogeneity. Subgroup analyses showed that the use of lipophilic statins was associated 
reduced risk of AD (aRR = 0.639; CI = 0.449–0.908; p = 0.013), while the use of hydrophilic statins reduced 
the risk of incident AD at the statistical trend level (aRRs = 0.619; CI = 0.383–1.000; p = 0.050) (Fig. 3C). We 
could not perform the association between statins use (current and former users) and the risk of AD because of 
recruited studies less than 3. In meta-regression analyses, the percentage of white participants (slope = 0.006; 
p = 0.047), study duration (slope = −0.063; p = 0.033), and percentage of apoE4 > or = 1 (apoE4 carriers) 
(slope = −0.042; p = 0.044) emerged as significant moderators of outcomes (Supplementary material Table S5).
Statins use and Incident Vascular Dementia. Across 3 studies8,22,23, no significant difference in the inci-
dence of VaD was observed between participants with statins treatment and those without (aRR = 1.012, 95% 
CI = 0.620–1.652, p = 0.961). There was evidence of publication bias through Egger’s regression (t value = 17.932, 
df = 1, p = 0.035). We used Duval and Tweedie’s trim and fill procedure toward left to adjust effect size estimates 
to publication bias and the results remained non-significant (aRR = 0.720, 95% CI = 0.428–1.210). No significant 
heterogeneity was found (Q value = 3.256, df = 2, I2 = 38.581, p = 0.196) (Fig. 4B).
Statin use and Incident MCI. Across 6 studies9,16,36,42,45,48, participants who were using statins were signifi-
cantly less likely to develop MCI compared with those who did not receive statins (aRR = 0.737, 95% CI = 0.556–
0.976, p = 0.033). There was evidence of publication bias as indicated by Egger’s regression (t value = 4.051, df = 4, 
p = 0.015). We used Duval and Tweedie’s trim and fill procedure toward the right to adjust effect size estimates to 
publication bias and the results tend to insignificance (aRR = 0.923, 95% CI = 0.713–1.193). Additionally, there 
was significant heterogeneity was found (Q value = 12.330, df = 5, I2 = 59.449, p = 0.031). Therefore, potential 
sources of heterogeneity were explored.
Sources of Heterogeneity. In meta-regression analyses, the percentage of male proportion 
(slope = −0.008; p = 0.022) and number of covariables (slope = −0.114; p = 0.011) emerged as significant mod-
erators of outcomes (Supplementary material Table S5).
Adverse Events. None of studies, except one43, reported information regarding side effects during follow-up 
period. Hippisley-Cox et al.43 reported that the use several statins including simvastatin, atrovastatin, fluvasta-
tin, pravastatin, and rosuvastatin increased the risk of liver dysfunction (simvastatin 10–20 mg/day, for women, 
adjusted HR [aHR] = 1.47, 95% CI = 1.32–1.63, for men, aHR = 1.35, 95% CI = 1.25–1.54), myopathy (simvasta-
tin 10–20 mg/day, for women, aHR = 2.91, 95% CI = 2.19–3.88, for men, aHR = 6.12, 95% CI = 4.97–7.55), acute 
renal failure (simvastatin 10–20 mg/day, for women, aHR = 1.38, 95% CI = 1.10–1.74, for men, aHRs = 1.39, 95% 
CI = 1.14–1.70), and cataract (simvastatin 10–20 mg/day, for women, aHR = 1.30, 95% CI = 1.24–1.36, for men, 
aHR = 1.32, 95% CI = 1.24–1.39).
Discussion
The current meta-analysis of 25 cohort studies provides the most comprehensive meta-analytic evidence regard-
ing the effects of statins on incident all-caused dementia, AD, VaD, and MCI. We found that statins users, without 
baseline cognitive dysfunction, had a significantly reduced risk of developing all-caused dementia, AD, and MCI. 
Statins use was associated with a 15.1%, 28.1%, and 26.3% lowered risk of developing all-caused dementia, AD, 
and MCI respectively. Nevertheless, the few studies available provided no evidence that statins use could prevent 
the onset of VaD. In addition, the larger body of data included in the current meta-analysis compared to previous 
similar efforts37,52 allowed a more accurate exploration of potential sources of heterogeneity.
The current meta-analysis suggests that statins may offer a more significant preventative benefit for neu-
rodegenerative dementing illness such as AD than for all-caused dementia31–34,37,53. Besides, both our study 
(aRR = 0.737, 95% CI = 0.556–0.976) and previous work by Richardson et al. found the statins appear to provide 
the stronger protective effects for incident MCI (aRR = 0.66, 95% CI: 0.51–0.86). However, compared to the 
Richardson study, we added two studies and enrolled more subjects in the present meta-analysis36,45. Nonetheless, 
the evidence base appears to consistently indicate that statins may protect against early stage cognitive decline, 
such as MCI8,9,36. A longitudinal study of 6,600 subjects with normal cognition or MCI even showed statins exert 
AD = Alzheimer’s Disease; ApoE = Apolipoprotein E; BMI = Body Mass Index; CABG = Coronary artery 
bypass graft; CAD = Cardiovascular disease; CASI = Cognitive ability screening instrument; CCI = Charlson 
comorbidity index; CHD = Coronary Heart Disease; DM = Diabetes; EMR = Electronic Medical Records; 
HTN = Hypertension; HVLT = Hopkins Verbal Learning Test; LDL-C = Low-density lipoprotein cholesterol; 
LLA = Lipid lowering agents; MCI = Mild cognitive impairment; MR = Mental retardation; N/A = Not 
Applicable; NSU: No Statin Use; OHA = Oral hypoglycemic agents; SEVLT: Spanish and English Verbal 
Learning Test; SSRI = Selective serotonin reuptake inhibitor; SU: Statin User; TCA = tricylic antidepressants.
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a cognitive protection among those with normal cognition at baseline but not MCI, indicating statins might exert 
benefit before MCI status54.
Importantly, this is the first meta-analysis to examine the association between statins use and risk of VaD, 
although no significant differences emerged (aRR = 1.012, 95% CI = 0.620–1.652, p = 0.961). Atherosclerosis 
is considered to be responsible for diffuse periventricular white matter abnormalities, which are one of major 
pathophysiological mechanisms of VaD55. We hypothesized that statins may reduce the development of VaD 
Figure 3. Subgroup analyses. (A) The use of hydrophilic compared to lipophilic statins and incident all-
caused dementia; (B) current versus former statins users and incident all-caused dementia; and (C)The use of 
hydrophilic compared to lipophilic statins and incident Alzheimer’s Disease. Squares depict individual studies 
and diamonds depict summary effect size estimates (aRRs).
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via alleviating or preventing cerebrovascular disease, which are the main risk factors for VaD56–58. However, the 
negative findings between VaD and statins from this meta-analysis might be due to the few number of included 
studies. Nevertheless, we considered adjust relative risks of individual studies. Therefore, it is possible that statins 
might not offer an independent preventative benefit for VaD. Besides, these studies did not account for important 
factors (such as plasma lipids or apolipoprotein E genotype)8,22,23, which might influence the results. Thus, clearly 
more research is required to consider if statins may confer a protective effect over future VaD.
The exact mechanism of statins on cognitive protection in older adults has not been elucidated but it might 
include pleiotropic effects on several mechanistic pathways. First, in animal models, statins could decrease cho-
lesterol levels and attenuate formation of beta-amyloid (β-amyloid), which is main component of amyloid plaques 
in the brains of individuals with AD59. Besides, statins in preclinical models reduced brain cholesterol levels, 
leading to lower neurofibrillary tangles60. These effects could result in lower risk of dementia. The meta-regression 
analysis of present study could support this hypothesis, showing statins provide higher cognitive protective effect 
in studies with higher percentage of cholesterol >200 mg/dl (slope = 0.018, p = 0.009). Second, statins may exert 
anti-inflammatory effects in the brain. For example, statins significantly reduced β-amyloid-induced produc-
tion of pro-inflammatory cytokines, such as interleukin (IL)-1beta, IL-6 and tumor necrosis factors-gamma 
(TNF-gamma) in the hippocampus61. This could be a relevant effect since accumulating evidence indicating that 
both peripheral immune activation and neuroinflammation are involved in the pathophysiology of AD. Third, 
Figure 4. Forest plot of random-effects meta-analyses of the use of statins and incidence of (A) Alzheimer’s 
Disease, (B) Vascular dementia, and (C) Mild cognitive impairment. Squares depict individual studies and 
diamonds depict pooled effect sizes (aRRs).
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statins exert cholesterol-independent effects (also referred to as pleiotropic effects), that showed antiproliferative 
and antithrombotic benefits and improved endothelial dysfunction, which plays import role in the initiation of 
inflammatory process-atherosclerosis62. Taken together, statins could attenuate the cognitive decline via, at least 
in partial, decreasing anti-inflammatory action, attenuate formation of beta-amyloid (β-amyloid) and neurofibril-
lary by lowering cholesterol levels, and pleiotropic effects.
Our subgroup analyses show that significant reduced risks of all-caused dementia and marginal significances 
of lower risk of AD were found for hydrophilic statins. In addition, lipophilic statins could reduce risks of AD 
but not all-caused dementia. The protective effects of statins on preventing the onset of dementia which can 
emerge as a function of their pharmacokinetic properties remains under debate, with some studies favoring 
lipophilic statins38 but other showing no difference between hydrophilic and lipophilic statins10. In the current 
meta-analysis, hydrophilic and lipophilic statins significantly decreased the incidence of all-caused dementia 
and AD, respectively. Studies had shown the lipophilic statins can more easily than hydrophilic statins cross the 
blood-brain barrier, thus potentially providing more robust benefits for the prevention of neurodegenerative 
disease63,64. Our results suggest that hydrophilic statins could exhibit more extensive protective effects than lipo-
philic statins in preventing all-caused dementia and possibly AD. However, these results should be interpreted 
cautiously. It is noteworthy that both forest plots of hydrophilic and lipophilic statins tended to the left, which 
means favor statins‘ preventive effect on all-caused dementia and AD. Although some results such as associa-
tion between lipophilic statins and all-caused dementia and between hydrophilic statins and AD did not show 
significant differences, these make us not to reject the null hypothesis. Additionally, two recent epidemiological 
studies without non-statins comparator groups and therefore did not meet eligibility criteria for this study war-
rant mentioning. Zissimopoulos et al. used administrative claims data from Medicare beneficiaries to analyze the 
association between statin use with AD onset. They found lipophilic (simvastatin and atorvastatin) and hydro-
philic (pravastatin and rosuvastatin) generally were associated with reduced risk of AD depend on different races 
and sex65. In contrast, Sinyavskaya et al. reported lipophic statins (simvastain, atorvastatin, fluvastatin) were not 
associated with decreased incident of AD compared to hydrophilic statins (pravastain, rosuvastatin), using data 
from the UK Clinical Practice Research Datalink cohort of patients aged 60 to 95 years who were followed for 
a median of 5.9 years66. Therefore, the association of statins and AD and all-caused dementia might vary across 
different properties of statins, sex, and race/ethnicity. Future intervention studies are needed to better study the 
differential effects of hydrophilic and lipophilic statins on preventing incidence of dementia or otherwise as novel 
neuroprotector agents for MCI and AD.
The meta-regression analysis showed several variables were associated with statins use and the relation-
ship with the risk of all-caused dementia, AD and MCI. One of interesting findings was statins expressed lesser 
cognitive preventive effect in studies with higher percentage of white ethnicity in both all-caused dementia 
(slope = 0.005, p = 0.006) and AD (slope = 0.006, p = 0.047). Pharmacokinetic differences exist among different 
races67. Caucasian subjects tend to have lower plasma exposure to and its metabolites compared non-Caucasian 
subjects in several types of statins68,69, leading to lesser treatment effect. Nearly all of recruited studies are from 
Western countries. The sample sizes for other ethnicities are smaller, and the estimates might be less precisely 
measured. Future studies to address neuroprotective effects of statins in difference ethnicities are needed. In 
addition, apoE4 allele is a major genetic risk factor for both all-caused dementia and AD70. It is reasonable that 
apoE might alter the effects of statin on the cognition as apoE plays a critical role in the transport of cholesterol 
and fats to the brain71. Indeed, we did find significant negative association between presence of apoE4 and AD 
(slope = −0.042, p = 0.044), although not in all-caused dementia.
Some important cofounders should be considered. For example, studies have shown that different levels of 
social relationship72 and physical exercise73 might relate to the development of dementia. To determine the inten-
sity of social involvement is challenge and lack of objective measures in the past. Currently, there is an increasing 
number of commercially available devices (wearable activity trackers), which provide researchers with secure 
and precise means to collect, and analysis data generated by health devices74. This wearable technology could be 
integrated into the future cohort studies to off real-time monitoring to improve dementia prevention and more 
person-centered care.
Several limitations should be addressed. First, the study is a pooled synthesis of observational studies which 
are susceptible to the effects of chance, bias and confounding and thus, results should be interpreted cautiously. 
Second, we excluded studies that considered cognitive function change as endpoint and did not discuss the clin-
ical trajectory at every clinical assessment point until the last assessment. However, this is beyond the scope of 
current meta-analysis. Although the U.S. Food and Drug Administration (FDA) issued a statement regarding 
poor cognitive status associated with statin use in 2012, no convincing evidence so far support this warning75,76. 
Nevertheless, it would be potentially more informative to analysis all studies with investigating the effect of stat-
ins on the cognitive function change measured by objective tools. Future studies could be conducted to address 
this issue. Third, we only included peer-reviewed articles published in English language and thus it is possible 
that we might have missed some non-English studies. However, no publication bias was evident for almost all 
our outcomes. Fourth, meta-regression could not be performed for studies of VaD and MCI due to few datasets 
available. Fifth, none of the included studies used a propensity score or a matching criterion between statins users 
or not and so another potential bias could be present in our findings. In an attempt, to provide a better control of 
potential confounders we also performed meta-analyses considering the most fully adjusted outcome measures 
of individual studies. Finally, several diagnostic criteria for dementia (DSM, ICD, and NINCDS-ADRDA etc.) as 
well as different methods to assess the use of statins (electronic medical records, pharmacy records, and medica-
tion inspection etc.) across included studies may also limit the comparability and synthesis of studies included in 
this meta-analytic review.
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Conclusions
The use of statins appears to have beneficial effects in reducing incidence of all-caused dementia, AD, and MCI, 
but not VaD. Subgroup analyses suggest that hydrophilic and lipophilic statins showed a beneficial effect in pre-
venting all-caused dementia and AD, respectively. Thus, our data suggest that the use of statins may confer a 
potential benefit for the prevention of dementia.
Methods and Materials
The current systematic review and meta-analysis was in line with the Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses (PRISMA) guidelines77 (Supplementary material Table S6). This systematic 
review and meta-analysis was approved by the Institutional Review Board of the Tri-Service General Hospital 
(TSGHIRB: B-105-12). Two investigators (CSC and PTT) have independently performed database searching, 
study selection, data extraction, and the rating of the methodological quality of included studies. Disagreements 
were resolved through consensus.
Database Searching. The PubMed, ScienceDirect, Psychology and Behavior Sciences Collection, 
ClinicalTrials.gov and Cochrane library were systematically searched from inception up until December 27th, 
2017 (Supplementary material Table S7). The search string used for the electronic database search was provided 
in the Supplementary material. The search strategy was augmented through hand searching the reference lists of 
included articles, as well as previous reviews52,76 and meta-analysis37 on the topic.
Eligibility Criteria and Study Selection. The following eligibility criteria were applied: (1) prospective 
cohort studies investigating the effects of statins vs. participants not taking statins; (2) participants had to be 
cognitively healthy at baseline and without a history of cognitive dysfunction; (3) outcome measures had to 
include either incident all-caused dementia or otherwise specific-caused dementia (i.e. AD or VaD) or mild cog-
nitive impairment (MCI) based on Diagnostic and Statistical Manual of Mental Disorders (DSM)2, International 
Classification of Diseases (ICD)78, National Institute of Neurological and Communicative Disorders and Stroke 
and the Alzheimer’s Disease and Related Disorders Association (NINCDS-ADRDA)79, diagnosis of MCI was 
based on Petersen’s, International Working Group, or National Institute on Aging-Alzheimer’s Association work-
groups diagnostic systems80,81; (4) with a follow-up period longer than one year and (5) peer-reviewed article 
written in English language.
The exclusion criteria were: (1) cross-sectional studies; (2) retrospective case-control studies; (3) clinical trials 
(i.e. randomized controlled trial (RCT)); and (4) studies that did not assess incident dementia or MCI at end-
point; (5) conference abstracts and studies published in languages other than English.
Methodological Quality Assessment. We used the Newcastle-Ottawa Scale (NOS) to rate the methodo-
logical quality of included studies82. For prospective cohort studies, the NOS considers three domains: selection 
of participants (maximum of four stars), comparability of groups (maximum of two stars), and measurement 
(maximum of three stars). Scores were ranged from 0 (the lowest) to 9 (the highest), and a score higher or equal 
to 7 indicated high methodological quality.
Data Extraction. The primary outcomes were risk of all-caused dementia, AD, VaD, and MCI considering 
statins use as the exposure. Pooled estimates between statins use and dementia were calculated by using fully 
adjusted RRs (aRRs) provide in each publication (further details in meta-analysis section).
A pre-specified data extraction form was used to extract data for this meta-analysis. Data was extracted for 
each study included basic characteristics of participants (age, percentage of male, education in years, percent-
age of whites), study duration (follow-up time, in years), substance use (percentage of alcohol and smoking), 
prevalence of co-occurring medical conditions (cardiovascular, cerebrovascular, diabetes mellitus [DM], hyper-
tension), percentage of > or = 1 Apolipoprotein E epsilon 4 (ApoE4) (ApoE4 carrier), cholesterol > 200 mg/dl 
and percentage of overweight/obese people (BMI > 25, (%)). Diagnosis of all-caused dementia, AD, and VaD 
were based on DSM-III-R10,25,42,50, DSM-IV9,13,18,21,38,39,41,51, NINCDS-ADRDA9,10,13,16,18,21–23,39,42,51, ICD-916,40, or 
ICD-10 41,49,50; some studies did not provide the criteria for interested outcome8,19,43,44,46,47; diagnosis of MCI was 
defined based on Petersen criteria42, probable prodromal AD16 or decline of specific cognitive decline (e.g. modi-
fied mini-mental state examination, Verbal Learning Test and Consortium to Establish a Registry for Alzheimer’s 
Disease (CERAD) word list)9,36,45,48.
When data were not available in the articles, we electronically contacted the authors in at least two separate 
occasions to provide additional data.
Meta-analysis. All meta-analytic procedures were performed with the Comprehensive Meta-Analysis 
software, version 3 (Biostat, Englewood, NJ) software. For each meta-analysis, we considered the risk measure 
of each study which was most fully adjusted for potential confounders. We conducted the meta-analyses with 
random-effects models due to the anticipated heterogeneity across studies. Heterogeneity was assessed with the 
Cochran Q test and the I2 metric83. We changed ORs to RRs if data available in three recruited studies41,50,51 using 
the formula suggested by Cochrane Hanbook84. Therefore, the effect size (ES) and its 95% confidence interval 
[CI] was defined as RRs to indicate the difference of the incident rate of all-caused dementia (including AD, VaD, 
or MCI) as a function of statins use (exposure). A similar analysis was undertaken pooling the RR of each study, 
adjusted for the highest number of potential confounders available.
Subgroup analyses stratified by pharmacokinetic properties of statins (hydrophilic vs lipophilic), as previous 
studies, showed inconsistent results regarding the protective effect of hydrophilic and lipophilic statins on cog-
nition10,38. Atovastatin, fluvastatin, pravastatin, and rosuvastatin are hydrophilic statins, whereas cerivastatin, 
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lovastatin, and simvastatin are more lipophilic statins84,85. Besides, status of statins usage (current and former use) 
was undertaken. Subgroup analyses were performed when data from at least three datasets.
Publication bias was assessed via a visual inspection of funnel plots and by means of the Egger’s regression 
test86. Additionally, to account for publication bias, we used the trim-and-fill method, based on the assump-
tion that the effect sizes of all the studies were normally distributed around the center of a funnel plot; in the 
event of asymmetry, this method adjusts for the potential effect of unpublished (trimmed) studies86. In addi-
tion, we conducted a meta-regression analysis using an unrestricted maximum likelihood method to explore 
potential moderators. The following variables were considered for meta-regression analyses: mean age, male 
gender (%), education (years), percentage of ethnicity, study duration (follow-up duration, in years), and preva-
lence comorbidities (cardiovascular, cerebrovascular, DM, and hypertension), percentage of presence of ApoE4 
(ApoE4 carriers), total NOS scores, BMI > 25, cholesterol > 200 mg/dl and numbers of covariates adjusted. The 
meta-regression procedure was only undertaken when moderator variables were available from more than 5 
individual studies. Statistical significance was set as two-tailed P value less than 0.05.
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